Abstract:The World Health Organization (WHO) recently published a list of fungal priority pathogens, including Candida albicans and C. auris. The increased level of resistance of Candida is raising concern, considering the availability of only four classes of medicine. The WHO is seeking novel agent classes with different targets and mechanisms of action. Targeting Candida metacaspases to control intrinsic cell death could provide new therapeutic opportunities for invasive candidiasis. In this review, we provide the available evidence for Candida cell death, describe Candida metacaspases, and discuss the potential of Candida metacaspases to offer a new specific target. Targeting Candida cell death has good scientific rationale given that the fungicidal activity of many marketed antifungals is mediated, among others, by cell death triggering. But none of the available antifungals are specifically activating Candida metacaspases, making this target a new therapeutic opportunity for non-susceptible isolates. It is expected that antifungals based on the activation of fungi metacaspases will have a broad spectrum of action, as metacaspases have been described in many fungi, including filamentous fungi. Considering this original mechanism of action, it could be of great interest to combine these new antifungal candidates with existing antifungals. This approach would help to avoid the development of antifungal resistance, which is especially increasing in Candida.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to find new antifungal treatment strategies, especially for the treatment of Candida. Specifically, the paper explores the possibility of controlling its intrinsic cell death by targeting the metacaspases of Candida, which may provide new treatment opportunities for invasive Candida infections. Currently, the types of available antifungal drugs are limited, and the problem of drug resistance is becoming increasingly serious. Therefore, it is particularly important to develop new drugs with different mechanisms of action. ### Background of the paper 1. **Severity of Candida infections**: - There are more than 300 million cases of severe fungal infections worldwide every year, and 1.5 million people die from them. - Candida (especially *Candida albicans* and *Candida auris*) is one of the main pathogens causing invasive infections, and these infections are associated with a high mortality rate, especially in critically ill and immunocompromised patients. 2. **Limitations of existing antifungal drugs**: - Currently, only four classes of antifungal drugs (azoles, echinocandins, pyrimidines, and polyenes) are available for clinical use. - The resistance of Candida to these drugs is gradually increasing. In particular, *C. auris* has natural resistance to most available antifungal drugs, and some strains are even resistant to all drugs. 3. **Need for new treatment strategies**: - The World Health Organization (WHO) calls for the development of new drug classes with different targets and mechanisms of action to address the problem of drug resistance. - Targeting the metacaspases of Candida to induce cell death may be a potential new strategy. ### Main content of the paper 1. **Evidence of Candida cell death**: - The paper reviews various detection methods for Candida cell death, including fluorescence microscopy, TUNEL assay, DAPI staining, etc. - Many natural compounds and antimicrobial peptides have been proven to be able to induce apoptosis in Candida, and some of their mechanisms of action are related to the activation of metacaspases. 2. **Description of Candida metacaspases**: - Metacaspases belong to the C14 peptidase family in the CD family and are homologues of mammalian caspases. - The paper describes in detail the structural characteristics of metacaspases, including their calcium - dependent activity and the location of catalytic residues. - The three - dimensional structures of several metacaspases determined by X - ray crystallography show that they are significantly different from mammalian caspases in structure, which makes it possible to design specific drugs. 3. **Therapeutic potential of targeting metacaspases**: - Inducing cell death by activating the metacaspases of Candida may be a new treatment strategy. - This strategy may not only be effective against drug - resistant strains, but also can be used in combination with other existing antifungal drugs to avoid further development of drug resistance. ### Conclusion The paper emphasizes the potential value of developing new antifungal drugs by targeting the metacaspases of Candida. This strategy can not only overcome the drug resistance problem of existing drugs, but also may provide a broader scope of action for the treatment of invasive Candida infections. Future research needs to further explore the specific mechanisms of action of metacaspases and develop effective activators.

Specifically Targeting Metacaspases of Candida: A New Therapeutic Opportunity

Regulated Cell Death as a Therapeutic Target for Novel Antifungal Peptides and Biologics

Promising immunotherapeutic targets for treating candidiasis

Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond.

Exploring the antifungal potential of novel carbazate derivatives as promising drug candidates against emerging superbug, Candida auris

Targeting virulence: A new paradigm for antifungals

The progress and future of the treatment of Candida albicans infections based on nanotechnology

Optimising the Treatment of Invasive Candidiasis – A Case for Combination Therapy

Anti-fungal peptides: an emerging category with enthralling therapeutic prospects in the treatment of candidiasis

Exploring the Arsenal of Novel Antifungal Drug Targets for Combating Fungal Infections

Inhibition of Respiration of Candida albicans by Small Molecules Increases Phagocytosis Efficacy by Macrophages

Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species

Discovery of novel purinylthiazolylethanone derivatives as anti-Candida albicans agents through possible multifaceted mechanisms

Candida tropicalis-A systematic review to inform the World Health Organization of a fungal priority pathogens list

Cellular apoptosis and cell cycle arrest as potential therapeutic targets for eugenol derivatives in Candida auris

Targeting Virulence Factors of Candida albicans with Natural Products

A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in Candida Species

Current Perspectives of Antifungal Therapy: A Special Focus on Candida auris

Combination of fluconazole with natural compounds: A promising strategy to manage resistant Candida albicans infections

Candida albicans targets that potentially synergize with fluconazole

Spectrum of activity and mechanisms of azole–bisphosphonate synergy in pathogenic Candida